Open AccessTYK2 in Immune Responses and Treatment of Psoriasis
Author(s) -
Lin Shang,
Jiali Cao,
Siqi Zhao,
Jingya Zhang,
Yanling He
Publication year - 2022
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s380686
Subject(s) - tyrosine kinase 2 , janus kinase , psoriasis , stat protein , jak stat signaling pathway , immune system , signal transduction , immunology , pathogenesis , stat , biology , medicine , tyrosine kinase , cytokine , microbiology and biotechnology , stat3 , receptor , platelet derived growth factor receptor , growth factor
Tyrosine kinase 2 (TYK2), a key part of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, plays an integral role in the differentiation and immune responses of intrinsic immune cells and regulates the mediation of cytokines. TYK2 leads to inflammatory cascade responses in the pathogenesis of immune-mediated inflammatory diseases (IMIDs), especially psoriasis. Small-molecule TYK2 inhibitors are considered to be an effective strategy for modulating psoriasis. Here, we attempt to review the pro-inflammatory mechanisms of the JAK-STAT signaling pathway, the regulatory roles of TYK2 in the pathogenesis of psoriasis, and provide updates on ongoing and recently completed trials of TYK2 inhibitors.